Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting

NCT06324734 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06324734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06324734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 29, 2024
Completion date
July 15, 2024
Enrollment
2,506 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

using ncid database to assess the safety of olaparib in chinese patients with ovarian cancer by examining the incidence, seriousness, and severity of all ae